Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN

Biotechnology

Healthcare
$945.53 -0.90%

-$5.45 today

Market cap
$97.80B
Beta
0.24
P/E (TTM)
14.2
EPS (TTM)
$42.53
Dividend yield
0.60%
52W Low $506.38High $821.11

Volume 0.70M

Average 0.91M

REGN Sales of Investments

Cash received from selling or redeeming investments.

Regeneron Pharmaceuticals, Inc.NASDAQ: REGN

Sales of Investments · Q2 FY2026 · quarter ended Jun 2026

Sales of investments declines year over year

Q2 FY2026 sales of investments of $2.15B fell 0.9% year over year, ahead of the -14.4% change in trailing-twelve-month sales of investments. Sequentially, it fell 17.6% from the prior quarter. Over 3 fiscal years it compounded at +27.7% a year.

Context

  • Sales of investments amounted to 80.5% of revenue in FY2025, down 25.3 pp from a year earlier.
  • Sales of investments increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -0.9% holds above the trailing-twelve-month pace of -14.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$2.15B-17.6% QoQ
Last fiscal yearDec 2025
$11.55B-23.2% YoY
LTMJun 2026
$10.68B-14.4% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.9%——
1 year-23.2%——
3-year CAGR+27.7%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
11.55B USD
Year-over-year change
-23.2%
4-year CAGR
+51.1%

Sales of Investments vs competitors

How REGN compares with its peers on the latest reported figures

  • REGN's LTM Jun 2026 sales of investments of $10.68B is the largest of the 9 companies compared; the peer median is $185.47M.
  • Its year-over-year change of -14.4% is the 4th highest of 6, against a peer median of +33.1%.
  • Sales of investments amounts to 68.7% of revenue for REGN, versus a peer median of 1.3%.
REGN Competitors Peer median
Sales of Investments for REGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 2026$10.68B -14.4%+27.7%68.7%
GMABGenmab A/SLTM Jun 2026$2.03B —-28.7%49.1%
NVSNovartis AGLTM Jun 2026$1.19B -70.2%-61.9%2.1%
GILDGilead Sciences, Inc.LTM Jun 2026$599M +93.2%-23.1%2.0%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$314.34M +33.1%+37.0%4127.9%
BIIBBiogen Inc.LTM Jun 2026$56.6M +458.2%-74.2%0.6%
AZNAstraZeneca PLCLTM Sep 2026$11.78M -86.9%+46.1%0.0%
AMGNAmgen Inc.LTM Jun 2026$0 ——0.0%
OCULOcular Therapeutix, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding REGN) $185.47M+33.1%-25.9%1.3%

Competitors are the stored peer set for REGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income8.08B4.34B3.95B4.41B4.5B
Depreciation & Amortization286.2M341.4M421M482.9M543.7M
Deferred Income Tax(147.1M)(746.4M)(837.8M)(757.3M)(785.4M)
Stock-Based Compensation601.7M725M885M982.8M993.7M
Change in Working Capital(1.92B)(243.3M)(94.1M)(618.3M)532.6M
Accounts Receivables(1.93B)707.8M(338.8M)(554M)498.1M
Inventory(494.3M)(696.5M)(271.7M)(619.7M)(275.3M)
Accounts Payables866.1M(138.4M)598.6M735.1M736.8M
Other Working Capital(360.9M)(116.2M)(82.2M)(179.7M)(427M)
Other Non-Cash Items181.7M599.8M266.3M(82.2M)(810.6M)
Operating Cash Flow7.08B5.01B4.59B4.42B4.98B
Capital Expenditures(551.9M)(590.1M)(926.4M)(755.9M)(898.4M)
Acquisitions (Net)551.9M(230.3M)(54.9M)(16.5M)(3.3M)
Purchases of Investments(7.05B)(7.49B)(11.65B)(16.62B)(10.96B)
Sales of Investments2.22B5.55B9.44B15.03B11.55B
Other Investing Activities(551.9M)(1.03B)0(105.6M)0
Investing Cash Flow(5.38B)(3.78B)(3.19B)(2.47B)(629.1M)
Debt Repayment00000
Common Stock Issued1.67B1.52B1.15B1.47B635.9M
Common Stock Repurchased(2.68B)(2.53B)(2.24B)(3.63B)(3.97B)
Dividends Paid0000(370.3M)
Other Financing Activities(1.03B)(445.7M)(700.6M)(33.4M)(10.3M)
Financing Cash Flow(1.01B)(1.01B)(1.79B)(2.2B)(3.72B)
Effect of Forex Changes00(400K)(700K)300K
Net Change in Cash690.8M221.3M(381.6M)(248.8M)634.7M
Free Cash Flow6.53B4.42B3.67B3.66B4.08B

Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN

Intrinsic Alpha fair value

Locked

Current Price

$945.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.